{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:35:57Z","timestamp":1775036157460,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Most healthcare institutions require employees to be vaccinated against SARS-CoV-2 and many also require at least one booster.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>We determine the impact of vaccine type, demographics, and health conditions on COVID-19 vaccine side effects in healthcare professionals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>A COVID-19 immunity study was performed at the 2021 American Association for Clinical Chemistry Annual Scientific meeting. As part of this study, a REDCap survey with cascading questions was administered from September 9, 2021 to October 20, 2021. General questions included participant demographics, past and present health conditions, smoking, exercise, and medications. COVID-19 specific questions asked about SARS-CoV-2 vaccine status and type, vaccine-associated side effects after each dose including any boosters, previous infection with COVID-19, diagnostic testing performed, and type and severity symptoms of COVID-19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 975 participants (47.1% male, median age of 50 years) who completed the survey. Pfizer was the most commonly administered vaccine (56.4%) followed by Moderna (32.0%) and Johnson &amp;amp; Johnson (7.1%). There were no significant differences in vaccine type received by age, health conditions, smoking, exercise, or type or number of prescription medications. Side effects were reported more frequently after second dose (e.g., Moderna or Pfizer) (54.1%) or single\/only dose of Johnson &amp;amp; Johnson (47.8%). Males were significantly more likely to report no side effects (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), while females were significantly more likely to report injection site reactions (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), fatigue (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), headache (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), muscle pain (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), chills (<jats:italic>p<\/jats:italic> = 0.001), fever (<jats:italic>p<\/jats:italic> = 0.007), and nausea (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). There was a significant upward trend in participants reporting no side effects with increasing age (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). There were no significant trends in side effects among different races, ethnicities, health conditions, medications, smoking status or exercise. In multivariate logistic regressions analyses, the second dose of Moderna was associated with a significantly higher risk of side effects than both the second dose of Pfizer and the single dose of Johnson &amp;amp; Johnson.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and relevance<\/jats:title><jats:p>Younger people, females, and those receiving the second dose of Moderna had more COVID-19 vaccine side effects that per self-report led to moderate to severe limitations. As reported in other studies, the increase in side effects from Moderna may be explained by higher viral mRNA concentrations but be associated with additional protective immunity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.975781","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T06:43:50Z","timestamp":1664261030000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals"],"prefix":"10.3389","volume":"10","author":[{"given":"Stacy E. F.","family":"Melanson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Kumanovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanzy","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing H.","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan H. B.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Apple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin R.","family":"Ondracek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Wiencek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Victoria","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B2","unstructured":""},{"key":"B3","year":"2021","journal-title":"COVID-19 Vaccination Requirements for Health Care Providers and Suppliers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2002047","DOI":"10.2807\/1560-7917.ES.2021.26.3.2002047","article-title":"Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020","volume":"26","author":"Verger","year":"2021","journal-title":"Eurosurveillance."},{"key":"B5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/ijerph18020797","article-title":"As the pandemic progresses, how does willingness to vaccinate against COVID-19 evolve?","volume":"18","author":"Alley","year":"2021","journal-title":"Int J Environ Res Public Heal."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/cid\/ciab054","article-title":"Assessment of US healthcare personnel attitudes towards coronavirus disease 2019 (COVID-19) vaccination in a large university healthcare system","volume":"73","author":"Shaw","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e055085","DOI":"10.1136\/bmjopen-2021-055085","article-title":"National survey of attitudes towards and intentions to vaccinate against COVID-19: implications for communications","volume":"11","author":"Stead","year":"2021","journal-title":"BMJ Open."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.vaccine.2021.02.029","article-title":"Perspectives on the receipt of a COVID-19 vaccine: a survey of employees in two large hospitals in Philadelphia","volume":"39","author":"Kuter","year":"2021","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.15585\/mmwr.mm7039a2","article-title":"Disparities in COVID-19 vaccination status, intent, and perceived access for noninstitutionalized adults, by disability status \u2014 national immunization survey adult COVID module, United States, May 30\u2013June 26, 2021","volume":"70","author":"Ryerson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.puhe.2021.07.028","article-title":"Sociodemographic predictors of COVID-19 vaccine acceptance: a nationwide US-based survey study","volume":"198","author":"Mondal","year":"2021","journal-title":"Public Health."},{"key":"B11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.18683\/germs.2021.1283","article-title":"COVID-19: the pseudo-environment and the need for a paradigm change","volume":"11","author":"Stein","year":"2021","journal-title":"Germs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ijid.2021.04.047","article-title":"Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers","volume":"106","author":"Kadali","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.15537\/smj.2021.42.12.20210576","article-title":"Post-vaccination survey for monitoring the side effects associated with COVID-19 vaccines among healthcare professionals of Jazan province, Saudi Arabia","volume":"42","author":"Ahsan","year":"2021","journal-title":"Saudi Med J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"107098","DOI":"10.1016\/j.dib.2021.107098","article-title":"Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia","volume":"36","author":"Djanas","year":"2021","journal-title":"Data Br."},{"key":"B15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.23736\/S0031-0808.21.04435-9","article-title":"A snapshot global survey on side effects of cOvid-19 vaccines among healthcare professionals and armed forces with a focus on headache","volume":"63","author":"Perrotta","year":"2021","journal-title":"Panminerva Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1002\/jmv.26996","article-title":"Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms","volume":"93","author":"Kadali","year":"2021","journal-title":"J Med Virol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.26355\/eurrev_202106_26153","article-title":"Side effects after COVID-19 vaccinations among residents of Poland","volume":"25","author":"Andrzejczak-Grzadko","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B19","unstructured":"FDA"},{"key":"B20","unstructured":""},{"key":"B21","unstructured":"CDCVaccine Safety"},{"key":"B22","unstructured":""},{"key":"B23","unstructured":""},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/13548506.2021.1884274","article-title":"Impact of the COVID-19 outbreak on mental health status and associated factors among general population: a cross-sectional study from Pakistan","volume":"27","author":"Hayat","year":"2021","journal-title":"Psychol Health Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fpubh.2021.603602","article-title":"Impact of COVID-19 on the mental health of healthcare workers: a cross-sectional study from Pakistan","volume":"9","author":"Hayat","year":"2021","journal-title":"Front Public Heal."},{"key":"B26","doi-asserted-by":"publisher","first-page":"05028","DOI":"10.7189\/jogh.12.05028","article-title":"Prevalence of depression, anxiety, and stress among first responders for medical emergencies during COVID-19 pandemic: a meta-analysis","volume":"12","author":"Huang","year":"2022","journal-title":"J Glob Health."},{"key":"B27","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.ssmqr.2022.100130","article-title":"A qualitative analysis of psychosocial stressors and health impacts of the COVID-19 pandemic on frontline healthcare personnel in the United States","volume":"2","author":"Shah","year":"2022","journal-title":"SSM Qual Res Heal."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.4037\/ccn2022769","article-title":"Unmasking the truth of health care workers' well-being during the COVID-19 pandemic","volume":"42","author":"Bucca","year":"2022","journal-title":"Crit Care Nurse."},{"key":"B29","unstructured":""},{"key":"B30","unstructured":"CDC"},{"key":"B31","unstructured":"CDC"},{"key":"B32","unstructured":"CDC"},{"key":"B33","unstructured":"CDC"},{"key":"B34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fpubh.2022.834744","article-title":"Extension and severity of self-reported side effects of seven COVID-19 vaccines in Mexican population","volume":"10","author":"Camacho Moll","year":"2022","journal-title":"Front Public Heal."},{"key":"B35","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int J Pharm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41590-022-01212-3","article-title":"Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose","volume":"23","author":"Lustig","year":"2022","journal-title":"Nat Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1126\/scitranslmed.abm2311","article-title":"mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions","volume":"14","author":"Kaplonek","year":"2022","journal-title":"Sci Transl Med."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.06.21261707","article-title":"Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence","author":"Puranik","year":"2021","journal-title":"medRxiv [Preprint]."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.975781\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T06:43:56Z","timestamp":1664261036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.975781\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":39,"alternative-id":["10.3389\/fpubh.2022.975781"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.975781","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"975781"}}